Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIb, multicenter, randomized, double-blind, placebo controlled study to evaluate the safety, clinical efficacy and joint damage protection of two different doses of BMS-188667 [abatacept] using two dose schedules administered intravenously to subjects with active rheumatoid arthritis while receiving methotrexate

Next Previous
X
Search
Trial Profile

A phase IIb, multicenter, randomized, double-blind, placebo controlled study to evaluate the safety, clinical efficacy and joint damage protection of two different doses of BMS-188667 [abatacept] using two dose schedules administered intravenously to subjects with active rheumatoid arthritis while receiving methotrexate

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 08 Jul 2010 According to a BMS media release, European Commission has approved abatacept in combination with methotrexate for earlier use as first-line biologic after DMARD inadequate response for treatment of rheumatoid arthritis.
    • 26 May 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 10 Jun 2009 7-Year results of the long-term extension study were reported at the 2009 Annual European Congress of Rheumatology (EULAR), according to a Bristol-Myers Squibb media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top